NCT06333054已完成不适用
A Randomised, Controlled, Investigator Blinded, Comparative Study to Evaluate the Safety and Efficacy of a Head Lice Shampoo.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 109
- 试验地点
- 1
- 主要终点
- Cure Rate superior to 70% for the test product
研究概览
简要总结
This study is designed to compare the effectiveness and safety of test head lice shampoo (Test product) versus Goldgeist® Forte (reference product) following two applications.
详细描述
The primary objective was to show, that the cure rate after local application of Test head lice shampoo is better than a predefined limit. It had to be shown, that the Test head lice shampoo achieved a cure rate superior to 70% (cure rate at the end of day 10, corrected for re-infestation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Gender: male/female
- •Age: ≥ 1 year of age at the time of signing the informed consent
- •Patients with active head lice infestation of at least 5 living lice and 5 apparently living eggs
- •Patient or his/her guardian must be capable of understanding and providing written informed consent
- •The patient or his/her legal representative must give written informed consent, after having been oral and written informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subjects participating in the study
- •Patients must agree to not use any other ant-lice treatment for the duration of the study
- •Female patients:
- •are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent duringthe study. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel
- •or are women of non-childbearing potential, defined as: women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation),
- •or women who are ≥ 60 years of age.
排除标准
- •Known allergic reactions or hypersensitivity to the active ingredients used or the constituents
- •Patients with known skin allergies, multiple drug allergies or multiple allergies to cosmetic products
- •Pregnant or breast feeding women
- •Patient underwent treatment with any form of head lice treatment within the last 30 days prior to the Screening Visit (day 0)
- •Patients with chronic scalp disorder
- •Individuals on systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results
- •Subjects with hair longer than mid-back
- •Patients suspected or known not to follow instructions
- •Patients or his/her legal representative who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
- •Previous participation in this study or participation in any other investigational trial within the preceding 30 days
- •The patients are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •The patients are Oystershell employees or are employees of third-party organizations involved in the study.
研究组 & 干预措施
Silcap Shampoo
Experimental
Subjects with head lice were treated with Silcap Shampoo at visit 1 (day 0) and at visit 3 (day 7).
干预措施: Silcap Shampoo (Device)
Goldgeist® Forte
Active Comparator
Subjects with head lice were treated with Goldgeist® Forte at visit 1 (day 0) and at visit 3 (day 7).
干预措施: Pyrethrum Extract (Drug)
结局指标
主要结局
Cure Rate superior to 70% for the test product
时间窗: Day 10
The primary objective was to show, that the cure rate after local application of Test head lice shampoo is better than a predefined limit. It had to be shown, that the Test head lice shampoo achieved a cure rate superior to 70% (cure rate at the end of day 10, corrected for re-infestation).
次要结局
- Non-inferiority rate to the reference(Day 10)
- Local tolerability(Day 0 (at start and after treatment), Day 1, Day 7 (at start and after treatment), Day 10)
- Adverse Events (AEs)(Day 0 (at start and after treatment),Day 1, Day 7 (at start and after treatment), Day 10)
- Cure Rate superior to 70% for the reference product(Day 10)
- Skin irritation assessment(Day 0 (before, at start and after treatment),Day 1, Day 7 (before, at start and after treatment), Day 10)
- Esthetical effect of the anti-lice products(Day 0 (after treatment); day 7 (after treatment))
- Superior cure rate to the reference(Day 10)
- Global tolerability(Day 10)
- Eye irritation assessment(Day 0 (before, at start and after treatment),Day 1, Day 7 (before, at start and after treatment), Day 10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head LiceHead LiceNCT01803581Oystershell NV60
已完成
4 期
Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single ApplicationHead LiceNCT00995124Altman Biomedical Consulting Pty. Ltd.90
招募中
不适用
A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.Head LicePediculosis CapitisNCT05378477Oystershell NV220
已完成
不适用
A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.Head LicePediculosis CapitisNCT03617926Oystershell NV70
已完成
1 期
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.Actinic KeratosisNCT01788007Taro Pharmaceuticals USA443